155 related articles for article (PubMed ID: 38504270)
1. Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
Montemagno C; Jacquel A; Pandiani C; Rastoin O; Dawaliby R; Schmitt T; Bourgoin M; Palenzuela H; Rossi AL; Ambrosetti D; Durivault J; Luciano F; Borchiellini D; Le Du J; Gonçalves LCP; Auberger P; Benhida R; Kinget L; Beuselinck B; Ronco C; Pagès G; Dufies M
J Exp Clin Cancer Res; 2024 Mar; 43(1):86. PubMed ID: 38504270
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.
Fu Q; Xu L; Wang Y; Jiang Q; Liu Z; Zhang J; Zhou Q; Zeng H; Tong S; Wang T; Qi Y; Hu B; Fu H; Xie H; Zhou L; Chang Y; Zhu Y; Dai B; Zhang W; Xu J
Eur Urol; 2019 May; 75(5):752-763. PubMed ID: 30293904
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of ADAM8 inhibits the proliferation, migration, invasion, and tumorigenesis of renal clear cell carcinoma cells to enhance the immunotherapy efficacy.
Qu H; Mao M; Wang K; Mu Z; Hu B
Transl Res; 2024 Apr; 266():32-48. PubMed ID: 37992987
[TBL] [Abstract][Full Text] [Related]
7. Exosomal AP000439.2 from clear cell renal cell carcinoma induces M2 macrophage polarization to promote tumor progression through activation of STAT3.
Shen T; Miao S; Zhou Y; Yi X; Xue S; Du B; Tang C; Qu L; Fu D; Jia R; He H
Cell Commun Signal; 2022 Sep; 20(1):152. PubMed ID: 36153596
[TBL] [Abstract][Full Text] [Related]
8. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
Front Immunol; 2022; 13():890150. PubMed ID: 35686121
[TBL] [Abstract][Full Text] [Related]
9. New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments.
Dufies M; Grytsai O; Ronco C; Camara O; Ambrosetti D; Hagege A; Parola J; Mateo L; Ayrault M; Giuliano S; Grépin R; Lagarde N; Montes M; Auberger P; Demange L; Benhida R; Pagès G
Theranostics; 2019; 9(18):5332-5346. PubMed ID: 31410218
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
11. Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma.
Gibson JT; Norris KE; Wald G; Buchta Rosean CM; Thomas LJ; Boi SK; Bertrand LA; Bing M; Gordetsky JB; Deshane J; Li P; Brown JA; Nepple KG; Norian LA
PLoS One; 2020; 15(5):e0233795. PubMed ID: 32469992
[TBL] [Abstract][Full Text] [Related]
12. Regulator of G protein signaling-1 regulates immune infiltration and macrophage polarization in clear cell renal cell carcinoma.
Liu K; Xia D; Bian H; Peng L; Dai S; Liu C; Jiang C; Wang Y; Jin J; Bi L
Int Urol Nephrol; 2024 Feb; 56(2):451-466. PubMed ID: 37735297
[TBL] [Abstract][Full Text] [Related]
13. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
14. CCL2 as a potential therapeutic target for clear cell renal cell carcinoma.
Arakaki R; Yamasaki T; Kanno T; Shibasaki N; Sakamoto H; Utsunomiya N; Sumiyoshi T; Shibuya S; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
Cancer Med; 2016 Oct; 5(10):2920-2933. PubMed ID: 27666332
[TBL] [Abstract][Full Text] [Related]
15. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Grimm MO; Esteban E; Barthélémy P; Schmidinger M; Busch J; Valderrama BP; Charnley N; Schmitz M; Schumacher U; Leucht K; Foller S; Baretton G; Duran I; de Velasco G; Priou F; Maroto P; Albiges L;
Lancet Oncol; 2023 Nov; 24(11):1252-1265. PubMed ID: 37844597
[TBL] [Abstract][Full Text] [Related]
16. TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma.
Xu Y; Li L; Yang W; Zhang K; Zhang Z; Yu C; Qiu J; Cai L; Gong Y; Zhang Z; Zhou J; Gong K
J Exp Clin Cancer Res; 2023 Jul; 42(1):159. PubMed ID: 37415241
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database.
Koguchi T; Naito S; Hatakeyama S; Numakura K; Muto Y; Kato R; Kojima T; Kawasaki Y; Morozumi K; Kandori S; Kawamura S; Nishiyama H; Ito A; Habuchi T; Obara W; Ohyama C; Tsuchiya N; Kojima Y
Cancer Med; 2023 Nov; 12(22):20677-20689. PubMed ID: 37905674
[TBL] [Abstract][Full Text] [Related]
18. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Denize T; Hou Y; Pignon JC; Walton E; West DJ; Freeman GJ; Braun DA; Wu CJ; Gupta S; Motzer RJ; Atkins MB; McDermott D; Choueiri TK; Shukla SA; Signoretti S
Clin Cancer Res; 2022 Sep; 28(18):4045-4055. PubMed ID: 35802667
[TBL] [Abstract][Full Text] [Related]
20. M2-polarization-related CNTNAP1 gene might be a novel immunotherapeutic target and biomarker for clear cell renal cell carcinoma.
Li W; Meng X; Yuan H; Xiao W; Zhang X
IUBMB Life; 2022 May; 74(5):391-407. PubMed ID: 35023290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
